499 related articles for article (PubMed ID: 28073102)
1. Cancer resistance to therapies against the EGFR-RAS-RAF pathway: The role of MEK.
Martinelli E; Morgillo F; Troiani T; Ciardiello F
Cancer Treat Rev; 2017 Feb; 53():61-69. PubMed ID: 28073102
[TBL] [Abstract][Full Text] [Related]
2. Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.
Martinelli E; Troiani T; D'Aiuto E; Morgillo F; Vitagliano D; Capasso A; Costantino S; Ciuffreda LP; Merolla F; Vecchione L; De Vriendt V; Tejpar S; Nappi A; Sforza V; Martini G; Berrino L; De Palma R; Ciardiello F
Int J Cancer; 2013 Nov; 133(9):2089-101. PubMed ID: 23629727
[TBL] [Abstract][Full Text] [Related]
3. Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations.
Ahronian LG; Sennott EM; Van Allen EM; Wagle N; Kwak EL; Faris JE; Godfrey JT; Nishimura K; Lynch KD; Mermel CH; Lockerman EL; Kalsy A; Gurski JM; Bahl S; Anderka K; Green LM; Lennon NJ; Huynh TG; Mino-Kenudson M; Getz G; Dias-Santagata D; Iafrate AJ; Engelman JA; Garraway LA; Corcoran RB
Cancer Discov; 2015 Apr; 5(4):358-67. PubMed ID: 25673644
[TBL] [Abstract][Full Text] [Related]
4. Targeting
Baik CS; Myall NJ; Wakelee HA
Oncologist; 2017 Jul; 22(7):786-796. PubMed ID: 28487464
[TBL] [Abstract][Full Text] [Related]
5. MEK1/2 inhibitors in the treatment of gynecologic malignancies.
Miller CR; Oliver KE; Farley JH
Gynecol Oncol; 2014 Apr; 133(1):128-37. PubMed ID: 24434059
[TBL] [Abstract][Full Text] [Related]
6. [Focus on targeting the Ras-MAPK pathway: the Mek inhibitors].
Baldini C; Duchemann B; Hollebecque A; Routier É; Varga A; Gazzah A; Bahleda R; Besse B; Soria JC; Massard C
Bull Cancer; 2012 Sep; 99(9):865-74. PubMed ID: 25471668
[TBL] [Abstract][Full Text] [Related]
7. The biology and clinical development of MEK inhibitors for cancer.
Luke JJ; Ott PA; Shapiro GI
Drugs; 2014 Dec; 74(18):2111-28. PubMed ID: 25414119
[TBL] [Abstract][Full Text] [Related]
8. KRAS/BRAF mutation status and ERK1/2 activation as biomarkers for MEK1/2 inhibitor therapy in colorectal cancer.
Yeh JJ; Routh ED; Rubinas T; Peacock J; Martin TD; Shen XJ; Sandler RS; Kim HJ; Keku TO; Der CJ
Mol Cancer Ther; 2009 Apr; 8(4):834-43. PubMed ID: 19372556
[TBL] [Abstract][Full Text] [Related]
9. Epidermal growth factor receptor: pathway, therapies, and pipeline.
Goffin JR; Zbuk K
Clin Ther; 2013 Sep; 35(9):1282-303. PubMed ID: 24054705
[TBL] [Abstract][Full Text] [Related]
10. RAF suppression synergizes with MEK inhibition in KRAS mutant cancer cells.
Lamba S; Russo M; Sun C; Lazzari L; Cancelliere C; Grernrum W; Lieftink C; Bernards R; Di Nicolantonio F; Bardelli A
Cell Rep; 2014 Sep; 8(5):1475-83. PubMed ID: 25199829
[TBL] [Abstract][Full Text] [Related]
11. Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.
Friday BB; Adjei AA
Clin Cancer Res; 2008 Jan; 14(2):342-6. PubMed ID: 18223206
[TBL] [Abstract][Full Text] [Related]
12. MEK in cancer and cancer therapy.
Neuzillet C; Tijeras-Raballand A; de Mestier L; Cros J; Faivre S; Raymond E
Pharmacol Ther; 2014 Feb; 141(2):160-71. PubMed ID: 24121058
[TBL] [Abstract][Full Text] [Related]
13. Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies.
Benvenuti S; Sartore-Bianchi A; Di Nicolantonio F; Zanon C; Moroni M; Veronese S; Siena S; Bardelli A
Cancer Res; 2007 Mar; 67(6):2643-8. PubMed ID: 17363584
[TBL] [Abstract][Full Text] [Related]
14. Targeting RAS/RAF/MEK/ERK signaling in metastatic melanoma.
Wang AX; Qi XY
IUBMB Life; 2013 Sep; 65(9):748-58. PubMed ID: 23893853
[TBL] [Abstract][Full Text] [Related]
15. MEK inhibitors for the treatment of non-small cell lung cancer.
Han J; Liu Y; Yang S; Wu X; Li H; Wang Q
J Hematol Oncol; 2021 Jan; 14(1):1. PubMed ID: 33402199
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive predictive biomarker analysis for MEK inhibitor GSK1120212.
Jing J; Greshock J; Holbrook JD; Gilmartin A; Zhang X; McNeil E; Conway T; Moy C; Laquerre S; Bachman K; Wooster R; Degenhardt Y
Mol Cancer Ther; 2012 Mar; 11(3):720-9. PubMed ID: 22169769
[TBL] [Abstract][Full Text] [Related]
17. Targeting the MET gene for the treatment of non-small-cell lung cancer.
Gelsomino F; Facchinetti F; Haspinger ER; Garassino MC; Trusolino L; De Braud F; Tiseo M
Crit Rev Oncol Hematol; 2014 Feb; 89(2):284-99. PubMed ID: 24355409
[TBL] [Abstract][Full Text] [Related]
18. MEK and RAF inhibitors for BRAF-mutated cancers.
Belden S; Flaherty KT
Expert Rev Mol Med; 2012 Oct; 14():e17. PubMed ID: 23058743
[TBL] [Abstract][Full Text] [Related]
19. Targeting of MEK in lung cancer therapeutics.
Heigener DF; Gandara DR; Reck M
Lancet Respir Med; 2015 Apr; 3(4):319-27. PubMed ID: 25801412
[TBL] [Abstract][Full Text] [Related]
20. Mutations in BRAF and KRAS converge on activation of the mitogen-activated protein kinase pathway in lung cancer mouse models.
Ji H; Wang Z; Perera SA; Li D; Liang MC; Zaghlul S; McNamara K; Chen L; Albert M; Sun Y; Al-Hashem R; Chirieac LR; Padera R; Bronson RT; Thomas RK; Garraway LA; Jänne PA; Johnson BE; Chin L; Wong KK
Cancer Res; 2007 May; 67(10):4933-9. PubMed ID: 17510423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
